Modingam P et al., 2024: Disproportionality analysis of the WHO pharmacovigilance database for benzimidazole anthelmintics, covering 19,068 serious reports from 2000 to 2023. It finds disproportionate reporting of bone-marrow failure, leukopenia and hepatic disorders for the class.
Among 19,068 serious reports analyzed, significant disproportionality signals were found for benzimidazole derivatives compared to other anthelmintic drugs, notably for bone marrow failure and hypoplastic anemia (adjusted ROR 9.44 [5.01-18.9]), serious leukopenia (3.89 [2.64-5.76]), serious hepatic disorders (3.10 [2.59-3.71]), hepatitis (2.88, 95% CI 2.29-3.63) and serious urticaria (2.02, 95% CI 1.36-2.99).
Modingam P et al., 2024: Disproportionality analysis of the WHO pharmacovigilance database for benzimidazole anthelmintics, covering 19,068 serious reports from 2000 to 2023. It finds disproportionate reporting of bone-marrow failure, leukopenia and hepatic disorders for the class. Pharmacovigilance case/non-case study (WHO VigiBase 2000-2023); 19,068 serious individual case safety reports; France (Montpellier); drugs are albendazole, mebendazole, flubendazole, triclabendazole and others in the class; fenbendazole is not a licensed human drug and its share of reports is not separated in the abstract. Funder: not stated. Declared conflicts: authors declare no competing interests. Comparator: other anthelmintic drugs as the non-case reference. This is class-level signal detection, not proof of causation, and it cannot be used to quantify fenbendazole risk specifically. Study type: other.
